Author: Ken Dropiewski

BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence

– The TRACE-AI Network Study will deploy a scalable screening toolkit for ATTR-CM across large, diverse health system electronic health records (EHRs) aiming to identify individuals who have ATTR-CM earlier in their disease course and quantify the potential prevalence of undiagnosed ATTR-CM

Paragonix Technologies Signs Definitive Agreement to be Acquired by Getinge

WALTHAM, Mass.–(BUSINESS WIRE)–Paragonix Technologies, a leading organ transplant company, announced today that it has entered into a definitive agreement to be acquired by Getinge. This strategic acquisition will enhance Getinge’s global healthcare portfolio to also address needs in solid organ transplantation. Getinge’s global reach will expand access of Paragonix’s innovative […]

New Research Published in Nature Medicine Highlights the Benefit of Anti-Blood Clot Medications to Prevent Stroke Among Patients Undergoing Non-Cardiac Surgery

Risk Predication Tool, Developed by Anesthesiologists at Montefiore Health System and Albert Einstein College Medicine, May Reduce Adverse Outcomes BRONX, N.Y., Aug. 23, 2024 /PRNewswire/ — A new computational risk assessment prediction tool developed by anesthesiologists at Montefiore…

National Blood Clot Alliance Appoints Healthcare Veteran Erin VanDyke as Vice President, VTE Centers of Excellence

PHILADELPHIA, Aug. 22, 2024 /PRNewswire/ — The National Blood Clot Alliance www.stoptheclot.org, the nation’s leading patient advocacy organization dedicated to advancing the prevention, early diagnosis, and successful treatment of venous blood clots, has announced the appointment of…

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded subgroup data from the landmark REDUCE-IT® cardiovascular outcomes trial with VASCEPA®/VAZKEPA® (icosapent ethyl), as well as abstracts showcasing the mechanistic activity of eicosapentaenoic acid (EPA) that will be presented at the European Society of Cardiology (ESC) Congress in London, United Kingdom, August 30 – September 2, 2024.

Retension Pharmaceuticals Closes $10.4 Million Oversubscribed Series A to Fund Clinical Trials for Patients Suffering from Resistant and Uncontrolled Hypertension

FALLS CHURCH, Va.–(BUSINESS WIRE)–Retension Pharmaceuticals, Inc. is pleased to announce the successful closing of its Series A $10.4 million financing round to initiate a well-powered and controlled Phase 2 clinical study in patients with hypertension uncontrolled on two or more antihypertensives. Inhibition of PDE5 is a long-desired mechanism for enhancing NO-based […]